Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697742 | 0.87 | OPRM1 (0.55) | OPRM1SIGMAR1NR3C1KCNH2DRD2 | |
| SCHEMBL5755550 | 0.80 | OPRM1 (0.78) | OPRM1SIGMAR1NR3C1KCNH2OPRD1 | |
| SCHEMBL6984869 | 0.78 | ELANE (0.44) | OPRM1OPRK1ACHE | |
| SCHEMBL6986198 | 0.75 | TDP1 (0.54) | SIGMAR1ACHE | |
| SCHEMBL5756455 | 0.74 | OPRM1 (0.88) | OPRM1NR3C1KCNH2DRD2DRD3 | |
| SCHEMBL6654316 | 0.73 | OPRM1 (0.63) | OPRM1SIGMAR1OPRD1OPRK1 | |
| SCHEMBL6654313 | 0.73 | OPRM1 (0.63) | OPRM1SIGMAR1OPRD1OPRK1 | |
| SCHEMBL5756815 | 0.73 | OPRM1 (0.66) | OPRM1SIGMAR1NR3C1KCNH2DRD2 | |
| SCHEMBL5753484 | 0.73 | OPRM1 (1.00) | OPRM1NR3C1KCNH2OPRD1OPRK1 | |
| SCHEMBL5754539 | 0.72 | OPRM1 (0.94) | OPRM1NR3C1KCNH2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1292574-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-02-28 | — | — | US | disclosed |
| WO-2001098267-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885SIGMAR1 20/4885NR3C1 123/4885 |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885SIGMAR1 20/4885NR3C1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.